Literature DB >> 1595803

In situ and invasive vulvar cancer incidence trends (1973 to 1987).

S R Sturgeon1, L A Brinton, S S Devesa, R J Kurman.   

Abstract

OBJECTIVE: The objective of this study was to examine recent trends in the incidence of vulvar cancer. STUDY
DESIGN: Cases of in situ and invasive squamous cell vulvar cancer were identified from nine Surveillance, Epidemiology, and End Results cancer registries.
RESULTS: The incidence rate of in situ vulvar cancer nearly doubled between 1973 to 1976 and 1985 to 1987, whereas the rate of invasive squamous cell carcinoma remained relatively stable.
CONCLUSIONS: Possible reasons for this discordance include the following: (1) Women affected by the "sexual revolution" are not yet old enough to have invasive vulvar carcinoma; (2) early diagnosis and treatment of in situ carcinoma have mitigated anticipated increases in invasive vulvar carcinoma incidence; (3) in situ and invasive carcinomas of the vulva have different etiologies, with the sexually transmitted human papillomavirus involved in the etiology of in situ carcinoma and other factors involved with most invasive squamous cell carcinoma.

Entities:  

Mesh:

Year:  1992        PMID: 1595803     DOI: 10.1016/0002-9378(92)91623-i

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  19 in total

Review 1.  Drug therapy for gynaecological cancer in older women.

Authors:  R E van Rijswijk; J B Vermorken
Journal:  Drugs Aging       Date:  2000-07       Impact factor: 3.923

2.  Reduced prevalence of vulvar HPV16/18 infection among women who received the HPV16/18 bivalent vaccine: a nested analysis within the Costa Rica Vaccine Trial.

Authors:  Krystle A Lang Kuhs; Paula Gonzalez; Ana Cecilia Rodriguez; Leen-Jan van Doorn; Mark Schiffman; Linda Struijk; Sabrina Chen; Wim Quint; Douglas R Lowy; Carolina Porras; Corey DelVecchio; Silvia Jimenez; Mahboobeh Safaeian; John T Schiller; Sholom Wacholder; Rolando Herrero; Allan Hildesheim; Aimée R Kreimer
Journal:  J Infect Dis       Date:  2014-06-23       Impact factor: 5.226

3.  Adenoid cystic carcinoma of the uterine cervix.

Authors:  Masakazu Nishida; Kaei Nasu; Noriyuki Takai; Isao Miyakawa; Kenji Kashima
Journal:  Int J Clin Oncol       Date:  2005-06       Impact factor: 3.402

4.  Vulvar melanoma: relevant aspects in therapeutic management.

Authors:  Adriana Bittencourt Campaner; Gustavo Leme Fernandes; Fernanda de Araujo Cardoso; John Verrinder Veasey
Journal:  An Bras Dermatol       Date:  2017 May-Jun       Impact factor: 1.896

5.  Abdominoperineal Excisions in the Treatment Regimen for Advanced and Recurrent Vulvar Cancers-Analysis of a Single-Centre Experience.

Authors:  Sabine Hannes; Johanna M Nijboer; Alexander Reinisch; Wolf O Bechstein; Nils Habbe
Journal:  Indian J Surg       Date:  2015-04-24       Impact factor: 0.656

6.  Expression profiling of vulvar carcinoma: clues for deranged extracellular matrix remodeling and effects on multiple signaling pathways combined with discrete patient subsets.

Authors:  Kalliopi I Pappa; Jasmine Jacob-Hirsch; George D Vlachos; Ioanna Christodoulou; George Partsinevelos; Ninette Amariglio; Sofia Markaki; Aris Antsaklis; Nicholas P Anagnou
Journal:  Transl Oncol       Date:  2011-10-01       Impact factor: 4.243

7.  Use of the Sentinel Lymph Node Technique Compared to Complete Inguino-femoral Lymph Node Removal in Patients with Invasive Vulvar Cancer in Germany.

Authors:  F Kramer; H Hertel; P Hillemanns
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-02       Impact factor: 2.915

8.  Incidence of potentially human papillomavirus-related neoplasms in the United States, 1978 to 2007.

Authors:  George Kurdgelashvili; Graça M Dores; Samer A Srour; Anil K Chaturvedi; Mark M Huycke; Susan S Devesa
Journal:  Cancer       Date:  2013-04-11       Impact factor: 6.860

Review 9.  Carcinoma of the vulva: combined modality treatment.

Authors:  Gustavo S Montana
Journal:  Curr Treat Options Oncol       Date:  2004-04

10.  Prognostic factors and a value of 2009 FIGO staging system in vulvar cancer.

Authors:  Jacek J Sznurkowski; Tomasz Milczek; Janusz Emerich
Journal:  Arch Gynecol Obstet       Date:  2012-12-22       Impact factor: 2.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.